semaglutide flow trial kidney outcomes 2024 nejm hazard ratio Long-term of in obesity and cardiovascular disease in the SELECT Effects of semaglutide with and – Semaglutide in patients with overweight – Media Centre | EASD

[1] Many patients find the thigh particularly convenient for self-administration, as it offers good visibility and accessibility

McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE

Conditions like obesity with diabetes, sleep apnea, or hypertension call for evidencebased medical care rather than a supplement experiment

Escalating Obesity Epidemic and Weight-Loss Approvals World Health Organization data confirm that worldwide obesity prevalence nearly tripled between 1975 and 2024, affecting more than 890 million adults

These medications are increasingly popular for individuals with Type 2 diabetes and those seeking medical assistance with weight loss

N Engl J Med 2016;375:183444.ArticlePubMed 68